Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1381 to 1390 of 2683 total matches.
Colorectal Cancer Screening
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
(polyp) can prevent
cancer from developing.1
WHO SHOULD BE SCREENED — Routine screening for
colorectal ...
Most colorectal cancers arise from localized
adenomatous polyps in a process that may take
10 years or more. Early detection and removal of
a precancerous colonic lesion (polyp) can prevent
cancer from developing.
Deuruxolitinib (Leqselvi) for Severe Alopecia Areata
The Medical Letter on Drugs and Therapeutics • Oct 27, 2025 (Issue 1740)
alopecia areata: baricitinib (Olumiant) is approved for
use in adults,1 and ritlecitinib (Litfulo ...
The FDA has approved the oral Janus kinase (JAK)
inhibitor deuruxolitinib (Leqselvi – Sun) for treatment
of severe alopecia areata in adults. Two other oral
JAK inhibitors are approved for treatment of severe
alopecia areata: baricitinib (Olumiant) is approved for
use in adults, and ritlecitinib (Litfulo) is approved for
use in patients ≥12 years old.
Med Lett Drugs Ther. 2025 Oct 27;67(1740):174-6 doi:10.58347/tml.2025.1740b | Show Introduction Hide Introduction
Comparison Table: Antiviral Drugs for Seasonal Influenza for 2025-2026 (online only)
The Medical Letter on Drugs and Therapeutics • Oct 27, 2025 (Issue 1740)
illness ▪ FDA-approved for chemoprophylaxis of influenza in patients ≥1 year old $46.40
152.00 ...
View the Comparison Table: Antiviral Drugs for Seasonal Influenza for 2025-2026
Med Lett Drugs Ther. 2025 Oct 27;67(1740):e178-80 doi:10.58347/tml.2025.1740d | Show Introduction Hide Introduction
Drugs for Anxiety Disorders
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
for those ≤7 years
old or ≥65 years old because of insufficient evidence.1
PHARMACOTHERAPY
Several drug ...
Anxiety disorders (generalized anxiety disorder,
panic disorder, social anxiety disorder, and various
phobias) are the most common form of psychiatric
illness. They can be treated effectively with cognitive
behavioral therapy (CBT) and/or pharmacotherapy.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):121-8 doi:10.58347/tml.2023.1682a | Show Introduction Hide Introduction
Cardiovascular Effects of Some Antidiabetic Drugs
The Medical Letter on Drugs and Therapeutics • Aug 14, 2017 (Issue 1527)
diabetes.1
Recent findings that some of the newer second-line
drugs for type 2 diabetes ...
...
Antibacterial Drugs for Lyme Disease
The Medical Letter on Drugs and Therapeutics • May 17, 2021 (Issue 1624)
is also transmitted by I. scapularis, has been shown to
cause a similar illness in the upper Midwest.1-3 ...
Lyme disease in the US is caused by the spirochete
Borrelia burgdorferi, which is transmitted to humans
by Ixodes scapularis (blacklegged [deer] tick) and
I. pacificus (western blacklegged tick). Most cases of
Lyme disease occur in late spring and early summer
in northeastern and mid-Atlantic states, the upper
Midwest, and in northern California. B. mayonii, which
is also transmitted by I. scapularis, has been shown to
cause a similar illness in the upper Midwest.
Drugs for Chronic Insomnia
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
,
pharmacologic treatment should be added.1-3
BENZODIAZEPINE RECEPTOR AGONISTS —
Eszopiclone (Lunesta ...
Cognitive behavioral therapy for insomnia (CBT-I) is
recommended for initial treatment of chronic insomnia.
CBT-I includes stimulus control, sleep education
and hygiene, sleep restriction, relaxation training, and
cognitive therapy. When CBT-I alone is not effective,
pharmacologic treatment should be added.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):1-6 doi:10.58347/tml.2023.1667a | Show Introduction Hide Introduction
In Brief: Non-Inferiority Trials
The Medical Letter on Drugs and Therapeutics • Jan 10, 2011 (Issue 1355)
effective) than the
control in achieving the primary outcome.1,2 Non-inferiority
trials are appropriate ...
Several Medical Letter readers have asked about the meaning of non-inferiority trials. A non-inferiority trial is a comparison with an active control to determine whether the difference in response between the new drug and the active control is small enough (less than some pre-specified margin) to demonstrate that the new treatment is not less effective (or is only slightly less effective) than the control in achieving the primary outcome.1,2 Non-inferiority trials are appropriate when a proven effective treatment already exists and assigning some patients to a placebo group would be unethical...
In Brief: PCV13 for Adults 65 Years and Older
The Medical Letter on Drugs and Therapeutics • Oct 13, 2014 (Issue 1453)
pneumococcal polysaccharide vaccine (PPSV23;
Pneumovax 23), for all adults ≥65 years old.1
An unpublished ...
The US Advisory Committee on Immunization Practices (ACIP) now recommends routine immunization with 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13), in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23), for all adults ≥65 years old.1An unpublished, randomized, double-blind trial (CAPiTA) in about 85,000 adults ≥65 years old found that vaccination with PCV13 reduced first episodes of vaccine-type community-acquired pneumonia and invasive pneumococcal disease by 46% and 75%, respectively, compared to placebo.2Adults ≥65 years old who...
Addendum: Bupropion Safety in Pregnancy
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
Addendum: Bupropion Safety in Pregnancy
Volume 66 (Issue 1699) April 1, 2024
Our December 11 ...
Our December 11, 2023 article on Drugs for Depression included a single sentence on the safety of bupropion use during
pregnancy: "The safety of bupropion during pregnancy has
not been established; data from a bupropion pregnancy registry
suggested a possible increase in cardiac malformations."
A reader asked us to provide more information.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):56 doi:10.58347/tml.2024.1699c | Show Introduction Hide Introduction
